Association between tumor necrosis factor alpha gene polymorphisms and multiple myeloma risk: an updated meta-analysis

Hong, Yaping; Yu, Jing; Wang, Gang; Qiao, Wei-Song

doi:10.1080/16078454.2018.1552341

Cited by 6 publications

(4 citation statements)

References 35 publications

(41 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The presence of TNF-α polymorphisms has been associated with an increased risk of MM, as presented by Hong et al (28) in the meta-analysis. TNF-α 308 polymorphism has been rarely observed in patients with myeloma; however, it may have a role in the pathogenesis of MM.…”

Section: Cytokine Profilesmentioning

confidence: 85%

See 1 more Smart Citation

Modern markers for evaluating bone disease in multiple myeloma (Review)

et al. 2021

View full text Add to dashboard Cite

Multiple myeloma (MM) is a bone marrow neoplasia with increasing incidence compared to previous years. Although new therapeutic molecules have been introduced, it remains an incurable disease with severe repercussions to patients. For many patients, bone disease represents a severe problem often causing pain, pathological bone fractures, and spinal cord compression, which affects the quality of life. This article analyzes the main markers of bone destruction in MM as well as risk factors for severe bone damage. Bone complications have a negative impact on the quality of life of patients with MM, along with other associated complications (renal failure, hypogammaglobulinemia, osteolytic bone disease, hypercalcemia, anemia). The markers of bone destruction described in this article include: interleukin (IL)-6, tumor necrosis factor (TNF)-α, receptor activator of nuclear factor kappa-Β ligand (RANKL), osteoprotegerin (OPG), amino-and carboxy-terminal cross-linking telopeptide of type I collagen (NTX, CTX), human bone sialoprotein (BSP) and dickkopf-1 secreted glycoprotein (DKK1). The future practical applicability of this literature review would be the large-scale determination of markers of bone destruction that correlate with the negative evolution to complications of bone disease or the implications that these markers have in regards to treatment.

show abstract

Section: Cytokine Profilesmentioning

confidence: 85%

“…The heterogeneity of the group can explain the genetic diversity caused by daily living habits, environmental differences, the level of economic development, but also by the sex and age of the people enrolled in the study. The results showed that the TNFα-857 gene had significant associations with MM risk (28).…”

Section: Cytokine Profilesmentioning

confidence: 94%

Modern markers for evaluating bone disease in multiple myeloma (Review)

et al. 2021

View full text Add to dashboard Cite

show abstract

“…TNF is an important cytokine that acts in the bone marrow microenvironment, inducing plasma cell differentiation and MM development [ 42 ]. High levels of TNF seem to be associated with aggressive disease, while particular TNF polymorphisms are associated with an increased risk of MM development [ 43 , 44 ]. Additionally, RANK (TNFRSF11A) and OPG (TNFRSF11B) receptors are members of the TNF superfamily, and the balance between RANKL (TNFSF11) and OPG regulates the osteoclast-induced bone resorption [ 45 ].…”

Section: Discussionmentioning

confidence: 99%

A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma

Παπανώτα

Karousi

Kontos

et al. 2021

IJMS

View full text Add to dashboard Cite

Multiple myeloma (MM) is the second most common hematological malignancy, arising from terminally differentiated B cells, namely plasma cells. miRNAs are small non-coding RNAs that participate in the post-transcriptional regulation of gene expression. In this study, we investigated the role of nine miRNAs in MM. CD138+ plasma cells were selected from bone marrow aspirates from MM and smoldering MM (sMM) patients. Total RNA was extracted and in vitro polyadenylated. Next, first-strand cDNA synthesis was performed using an oligo-dT–adapter primer. For the relative quantification of the investigated miRNAs, an in-house real-time quantitative PCR (qPCR) assay was developed. A functional in silico analysis of the miRNAs was also performed. miR-16-5p and miR-155-5p expression was significantly lower in the CD138+ plasma cells of MM patients than in those of sMM patients. Furthermore, lower levels of miR-15a-5p, miR-16-5p, and miR-222-3p were observed in the CD138+ plasma cells of MM patients with osteolytic bone lesions, compared to those without. miR-125b-5p was also overexpressed in the CD138+ plasma cells of MM patients with bone disease that presented with skeletal-related events (SREs). Furthermore, lower levels of miR-223-3p were associated with significantly worse overall survival in MM patients. In conclusion, we propose a miRNA signature with putative clinical utility in MM.

show abstract

“…The p53 gene has polymorphism and contains coding and non-coding regions. Most of these polymorphisms contain single nucleotide polymorphisms (SNPs), and these polymorphisms are located on code 47 and code 72, and this code is functionally important because it is associated with coding for the arginine and proline alleles, which are associated with the occurrence of many types of cancer, including prostate cancer (Mostaid et al, 2021), my study (Doosti and Dehkordi, 2011;Mittal et al, 2011) indicated a highly significant association of genotypes (Homozygotes proline & Homozygote arginine) for the polymorphism of the p53Codon 72 gene with prostate cancer, while no significant relationship of the (Heterozygotes proline-arginine) genotype with the disease has been proven (Huang et al, 2004;Rogler et al, 2011) which did not prove a significant association between any of the genotypes of the Codon 72 p53 gene with prostate cancer, and justifies the reason for the emergence and disappearance of genotypes and its association or not with prostate cancer in the world to the variation of gene expression according to Environment and Ethnicity ) Hong et al, 2019).…”

Section: Molecular Diagnosis Of the Polymorphism In P53codon 72 Gene ...mentioning

confidence: 92%

Molecular detection of a polymorphism in the p53 codon 72 gene and its association with prostate cancer

Abdulla

Jawad

2022

ijhs

View full text Add to dashboard Cite

The role of the current study in detecting polymorphisms in the gene P53codon72, a gene that has morphological polymorphism and has an important role in the incidence of diseases, especially cancers such as prostate cancer, samples for the study were collected from 50 patients with prostate cancer from the auditors of the Imam Hussein Center for Cancer and Diseases Blood in Al-Hussein, peace be upon him, Teaching Hospital - Holy Karbala Governorate - Iraq After diagnosis by a specialist surgeon and 50 phenotypically healthy individuals as a control group, the (DNA) was extracted from the blood of both healthy and all patients study groups, and molecular detection of polymorphism of nucleotides was performed in Genes of the study using PCR-RFLP Molecular detection results in P53codon72 The results showed that there were highly significant differences between the genotype (Pro-Pro) and between the infected and healthy groups as well as the genotype (Arg-Arg), while there was no significant relationship between the genotype (Arg-Pro) and between the infected and healthy groups. The results also showed highly significant differences between the three genotypes (Arg/ Arg, Aro/Pro, Pro/Pro) and between the two groups sick and healthy.

show abstract

Association between tumor necrosis factor alpha gene polymorphisms and multiple myeloma risk: an updated meta-analysis

Cited by 6 publications

References 35 publications

Modern markers for evaluating bone disease in multiple myeloma (Review)

Modern markers for evaluating bone disease in multiple myeloma (Review)

A Cancer-Related microRNA Signature Shows Biomarker Utility in Multiple Myeloma

Molecular detection of a polymorphism in the p53 codon 72 gene and its association with prostate cancer

Contact Info

Product

Resources

About